Picture this: A planet united against the invisible threats of future pandemics, armed with knowledge and resources shared fairly across borders. That's the ambitious dream sparking excitement in global health circles today. But here's where it gets controversial—negotiations on who controls and profits from vital pathogen data could divide nations, raising questions about equity in a crisis. And this is the part most people miss: These talks aren't just bureaucracy; they're building the foundation for a safer world, one shared virus sample at a time.
In a promising turn of events, WHO member states wrapped up their most recent intensive discussions on establishing the world's inaugural Pathogen Access and Benefit Sharing (PABS) system. To underscore their collective dedication and the pressing need to bolster defenses against upcoming health emergencies, countries have opted to pick up the threads sooner than planned, with a continuation slated for early 2026.
The group convened for the fourth session of the Intergovernmental Working Group (IGWG) focused on the WHO Pandemic Agreement (accessible at https://www.who.int/about/governance/world-health-assembly/intergovernmental-working-group-on-the-who-pandemic-agreement) in Geneva from December 1 to 5, 2025. Recognizing the depth of the topics, participants chose to prolong this negotiation cycle, scheduling a follow-up from January 20 to 22, 2026.
Set up by the World Health Assembly, the IGWG has been tasked with multiple objectives, chief among them drafting and hashing out the PABS annex attached to the WHO Pandemic Agreement. For those new to this concept, think of PABS as a global framework designed to democratize access to pathogens—the microscopic organisms that cause diseases like COVID-19—and their genetic blueprints. Member states have called for a dedicated PABS platform that would function as an international hub for exchanging these materials and the ensuing benefits, such as new treatments or vaccines, in a manner that's prompt, just, and open. This initiative aims to foster a more robust and balanced strategy for tackling the inevitable next outbreak, ensuring that no country is left scrambling in isolation. For example, during the COVID-19 pandemic, uneven access to virus samples delayed vaccine development in some regions, highlighting why fair sharing could save lives and economies worldwide.
"Halfway through crafting the Pathogen Access and Benefit-Sharing (PABS) system, I'm heartened by the strides made in paving the way for quicker, more inclusive worldwide responses to potential pandemics," remarked IGWG Bureau co-chair Mr. Matthew Harpur from the United Kingdom. "Nations have shown genuine resolve in seeking mutual understanding and reconciling viewpoints, all in pursuit of a robust PABS framework by the upcoming World Health Assembly."
Echoing this sentiment, IGWG Bureau co-Chair Ambassador Tovar da Silva Nunes of Brazil noted: "WHO member states have exhibited unwavering commitment to completing this crucial endeavor. The advancements in areas like accessibility, benefit distribution, and fundamental oversight lay a solid groundwork for progress. We're optimistic about crafting a comprehensive, well-rounded PABS system that serves humanity's best interests."
WHO Director-General Dr. Tedros Adhanom Ghebreyesus chimed in with enthusiasm: "This represents a once-in-a-generation chance and duty. I extend my gratitude to member states and the IGWG Bureau for stepping up. As the year winds down, we're poised to achieve agreement, polish the draft, and gear up for endorsement at next year's World Health Assembly. Collectively, we're forging a more resilient future against pandemics."
Prior to this fourth gathering, the IGWG Bureau facilitated informal discussions (details at https://www.who.int/news-room/events/detail/2025/11/24/default-calendar/informal-dialogues-of-the-intergovernmental-working-group-(igwg)-on-the-who-pandemic-agreement) involving key players such as private industry leaders, academic experts, lab professionals, and database managers for genetic sequences. These targeted exchanges will persist in the coming weeks to prime everyone for the January resumption. The sequence continues with the fifth IGWG meeting planned for February 9 to 14, 2026.
Yet, while the enthusiasm is palpable, the devil's in the details—especially when it comes to benefit-sharing. Who decides what 'fair' means? Could wealthy nations or corporations gain disproportionate advantages from poorer countries' biological resources, echoing past debates in biodiversity agreements? Some argue this might stifle innovation if companies fear losing proprietary secrets. But here's where it gets controversial: Others contend that without strict equity, the system risks reinforcing global inequalities, leaving vulnerable populations exposed once more. What do you think—should pharmaceutical giants have a louder voice in these talks, or should public health reign supreme? Is this a noble step toward global solidarity, or a potential recipe for new disputes? Share your opinions, agreements, or disagreements in the comments below; let's spark a conversation on building a better-prepared world!
/co-chair-and-vice-chair-of-igwg-at-fourth-meeting.tmb-1200v.jpg?sfvrsn=77fee812_1)
